Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase

• Published in: JAMA oncology Vol. 7; no. 5; p. 739
• Main Authors: Valero, Cristina, Lee, Mark, Hoen, Douglas, Zehir, Ahmet, Berger, Michael F, Seshan, Venkatraman E, Chan, Timothy A, Morris, Luc G T
• Format: Journal Article
• Language: English
• Published: United States 01.05.2021
• Subjects: B7-H1 Antigen - analysis; B7-H1 Antigen - genetics; Biomarkers, Tumor - genetics; Cohort Studies; Humans; Immune Checkpoint Inhibitors - pharmacology; Immunotherapy; Male; Microsatellite Repeats; Mutation; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - pathology; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Retrospective Studies

In June 2020, the US Food and Drug Administration approved the anti-programmed cell death 1 drug pembrolizumab for patients with malignant solid tumors of any histologic type with high tumor mutational burden (TMB; ≥10 mutations per megabase). The predictive value of this universal cutoff for high T...